Literature DB >> 21434879

Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human.

Michael M Morgan1, MacDonald J Christie.   

Abstract

Opioid agonists are the most effective treatment for pain, but their use is limited by side effects, tolerance and fears of addiction and dependence. A major goal of opioid research is to develop agonists that have high analgesic efficacy and a low profile for side effects, tolerance, addiction and dependence. Unfortunately, there is a serious lack of experimental data comparing the degree to which different opioids produce these effects in humans. In contrast, a wide range of experimental techniques from heterologous expression systems to behaviour assessment in whole animals have been developed to study these problems. The objective of this review is to describe and evaluate these techniques as they are used to study opioid efficacy, tolerance, addiction and dependence.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21434879      PMCID: PMC3229764          DOI: 10.1111/j.1476-5381.2011.01335.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  119 in total

1.  Meta-analysis of cue-reactivity in addiction research.

Authors:  B L Carter; S T Tiffany
Journal:  Addiction       Date:  1999-03       Impact factor: 6.526

2.  Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids.

Authors:  A C Barrett; C D Cook; J M Terner; R M Craft; M J Picker
Journal:  Psychopharmacology (Berl)       Date:  2001-11       Impact factor: 4.530

Review 3.  Prescription drug abuse: insight into the epidemic.

Authors:  S H Hernandez; L S Nelson
Journal:  Clin Pharmacol Ther       Date:  2010-08-04       Impact factor: 6.875

Review 4.  Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.

Authors:  P G Strange
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

5.  A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain.

Authors:  John T Farrar; John Messina; Fang Xie; Russell K Portenoy
Journal:  Pain Med       Date:  2010-08-30       Impact factor: 3.750

Review 6.  Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

Authors:  Margaret Haney
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

Review 7.  Opioid dependence and addiction during opioid treatment of chronic pain.

Authors:  Jane C Ballantyne; Steven K LaForge
Journal:  Pain       Date:  2007-05-04       Impact factor: 6.961

8.  mu-Opioid receptors: Ligand-dependent activation of potassium conductance, desensitization, and internalization.

Authors:  Veronica A Alvarez; Seksiri Arttamangkul; Vu Dang; Abdallah Salem; Jennifer L Whistler; Mark Von Zastrow; David K Grandy; John T Williams
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

9.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

Authors:  J R Traynor; S R Nahorski
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

10.  Buprenorphrine: demonstration of physical dependence liability.

Authors:  J Dum; J Bläsig; A Herz
Journal:  Eur J Pharmacol       Date:  1981-03-26       Impact factor: 4.432

View more
  79 in total

1.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

2.  The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats.

Authors:  Jenny L Wilkerson; Jasmine S Felix; Luis F Restrepo; Mohd Imran Ansari; Andrew Coop; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

3.  Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.

Authors:  Michael E Rothenberg; Michael Tagen; Jae H Chang; Janel Boyce-Rustay; Michel Friesenhahn; David H Hackos; Avis Hains; Dan Sutherlin; Michael Ward; William Cho
Journal:  Clin Drug Investig       Date:  2019-09       Impact factor: 2.859

Review 4.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

5.  Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.

Authors:  Nicole M Kennedy; Cullen L Schmid; Nicolette C Ross; Kimberly M Lovell; Zhizhou Yue; Yen Ting Chen; Michael D Cameron; Laura M Bohn; Thomas D Bannister
Journal:  J Med Chem       Date:  2018-09-24       Impact factor: 7.446

Review 6.  Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons.

Authors:  Vu C Dang; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 7.  Engineering endomorphin drugs: state of the art.

Authors:  Lawrence H Lazarus; Yoshio Okada
Journal:  Expert Opin Ther Pat       Date:  2012-01-04       Impact factor: 6.674

Review 8.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

Review 9.  μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.

Authors:  Marino Convertino; Alexander Samoshkin; Josee Gauthier; Michael S Gold; William Maixner; Nikolay V Dokholyan; Luda Diatchenko
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-12-06       Impact factor: 5.067

10.  The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids.

Authors:  Adrianne R Wilson-Poe; Edvinas Pocius; Melissa Herschbach; Michael M Morgan
Journal:  Pharmacol Biochem Behav       Date:  2012-10-10       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.